Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | MTOR | P42345 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046413 | 0.93 | NAMPT (0.46) | NAMPTHDAC1KITATR | |
| SCHEMBL3050002 | 0.92 | NAMPT (0.47) | NAMPTHDAC1KITATR | |
| SCHEMBL3054387 | 0.92 | NAMPT (0.47) | NAMPTHDAC1KITATR | |
| SCHEMBL3054878 | 0.91 | NAMPT (0.41) | NAMPTHDAC1KITATRPIK3CA | |
| SCHEMBL3057571 | 0.91 | NAMPT (0.48) | NAMPTPIK3CAMTOR | |
| SCHEMBL3051319 | 0.90 | NAMPT (0.40) | NAMPTHDAC1KITATRPIK3CA | |
| SCHEMBL485926 | 0.89 | PIK3CA (0.39) | NAMPTHDAC1KITPIK3CAMTOR | |
| SCHEMBL3061361 | 0.87 | NAMPT (0.40) | NAMPTHDAC1KITATRPIK3CA | |
| SCHEMBL3055649 | 0.86 | NAMPT (0.41) | NAMPTHDAC1KITMTORROCK2 | |
| SCHEMBL3054524 | 0.86 | HDAC1 (0.46) | NAMPTHDAC1ROCK2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | NAMPT 2/4885HDAC1 84/4885KIT 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.